Search

Displaying results 9171 - 9180 of 10000 in total
  1. Drug

    Trotabresib

    go.drugbank.com/drugs/DB17421
    Investigational

    Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.

  2. Drug

    OPC1

    go.drugbank.com/drugs/DB17944
    Experimental

    OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.[L47082]

  3. Drug

    NGN-101

    go.drugbank.com/drugs/DB18335
    Investigational

    NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene

  4. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.

  5. Drug

    Prosetin

    go.drugbank.com/drugs/DB18649
    Investigational

    Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]

  6. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

  7. Drug

    Ravidasvir

    go.drugbank.com/drugs/DB15652
    Investigational

    Ravidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).

  8. Drug

    Gevokizumab

    go.drugbank.com/drugs/DB12119
    Investigational

    Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. … Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.

  9. Drug

    N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide

    go.drugbank.com/drugs/DB03456
    Experimental

    This compound belongs to the n-acyl-alpha amino acids and derivatives. … These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom. It is known to target cathepsin K.

  10. Drug

    Neladalkib

    go.drugbank.com/drugs/DB21712
    Investigational

    The usage of the INN stem '-alkib' in the name indicates that Neladalkib is a ALK (anaplastic lymphoma kinase) inhibitor. … Neladalkib is under investigation in clinical trial NCT06765109 (Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC).

    Synonyms: an orally bioavailable ALK inhibitor (a macrocyclic compound containing nitrogen heterocycles)